Compare RGEN & EVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RGEN | EVR |
|---|---|---|
| Founded | 1981 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.2B | 11.7B |
| IPO Year | N/A | 2006 |
| Metric | RGEN | EVR |
|---|---|---|
| Price | $157.57 | $337.07 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 9 |
| Target Price | $170.90 | ★ $326.56 |
| AVG Volume (30 Days) | ★ 724.0K | 345.8K |
| Earning Date | 10-28-2025 | 10-29-2025 |
| Dividend Yield | N/A | ★ 1.00% |
| EPS Growth | N/A | ★ 61.11 |
| EPS | 0.03 | ★ 12.55 |
| Revenue | $707,890,000.00 | ★ $3,542,875,000.00 |
| Revenue This Year | $17.84 | $25.39 |
| Revenue Next Year | $12.57 | $16.43 |
| P/E Ratio | $5,097.58 | ★ $26.85 |
| Revenue Growth | 11.74 | ★ 27.03 |
| 52 Week Low | $102.97 | $148.63 |
| 52 Week High | $182.52 | $364.42 |
| Indicator | RGEN | EVR |
|---|---|---|
| Relative Strength Index (RSI) | 47.50 | 61.16 |
| Support Level | $160.11 | $319.69 |
| Resistance Level | $165.02 | $349.91 |
| Average True Range (ATR) | 4.97 | 10.83 |
| MACD | -1.27 | 2.97 |
| Stochastic Oscillator | 7.12 | 72.03 |
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 58% of 2024 revenue, while chromatography, proteins, and process analytics were 19%, 12%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.
Evercore is a leading independent investment banking advisory firm that generates most of its revenue through merger and acquisition and restructuring advisory services, with much smaller capital raising, equities trading, and investment management businesses. Founded in 1995, it has built a reputation for advising on some of the world's largest and most complex transactions. The firm operates globally with a strong presence in the US and Europe, serving corporations, financial sponsors, and government clients. Its business model emphasizes high-touch, conflict-free advice rather than balance sheet lending, allowing it to compete with larger bulge-bracket banks.